Aegle Therapeutics Corp. Announces Positive Data for the First Patient in a Phase I/IIa Clinical Trial Dosed With AGLE-102™, a Novel Extracellular Vesicle Therapy

Aegle Therapeutics Corp. announced positive 12-week data for the first patient enrolled in a Phase I/IIa clinical trial of AGLE-102™ for the treatment of severe second-degree burns.